Journal of Neuroimmunology
Volume 220, Issue 1 , Pages 43-51 , 30 March 2010

Involvement of phosphodiesterases in autoimmune diseases

  • Keren Mizrachi

      Affiliations

    • Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
    • The Leslie and Susan Gonda (Goldschmied) Multidisciplinary Brain Research Center, Bar-Ilan University, Israel
    • ,
  • Revital Aricha

      Affiliations

    • Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
    • ,
  • Tali Feferman

      Affiliations

    • Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
    • ,
  • Neta Kela-Madar

      Affiliations

    • Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
    • ,
  • Ilana Mandel

      Affiliations

    • Rappaport Faculty of Medicine, Technion, Haifa, Israel
    • ,
  • Tamar Paperna

      Affiliations

    • Rappaport Faculty of Medicine, Technion, Haifa, Israel
    • ,
  • Ariel Miller

      Affiliations

    • Rappaport Faculty of Medicine, Technion, Haifa, Israel
    • Carmel Medical Center, Haifa, Israel
    • ,
  • Avraham Ben-Nun

      Affiliations

    • Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
    • ,
  • Sonia Berrih-Aknin

      Affiliations

    • CNRS, France
    • ,
  • Miriam C. Souroujon

      Affiliations

    • Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
    • Department of Natural Sciences, The Open University of Israel, Israel
    • ,
  • Sara Fuchs

      Affiliations

    • Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
    • Corresponding Author InformationCorresponding author. Tel.: +972 8 9342618; fax: +972 8 9344141.

Received 22 September 2009 ,Revised 28 December 2009 ,Accepted 28 December 2009.

References 

  1. Aharonov A, Tarrab-Hazdai R, Silman I, Fuchs S. Immunochemical studies on acetylcholine receptor from Torpedo californica. Immunochemistry. 1977;14:129–137
  2. Anaya JM, Espinoza LR. Phosphodiesterase inhibitor pentoxifylline: an antiinflammatory/immunomodulatory drug potentially useful in some rheumatic diseases. J. Rheumatol. 1995;22:595–599
  3. Aricha R, Feferman T, Souroujon MC, Fuchs S. Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor. Faseb J. 2006;20:374–376
  4. Bailey SL, Schreiner B, McMahon EJ, Miller SD. CNS myeloid DCs presenting endogenous myelin peptides ‘preferentially’ polarize CD4+ T(H)-17 cells in relapsing EAE. Nat. Immunol. 2007;8:172–180
  5. Barabitskaja O, Foulke JS, Pati S, Bodor J, Reitz MS. Suppression of MIP-1beta transcription in human T cells is regulated by inducible cAMP early repressor (ICER). J. Leukoc. Biol. 2006;79:378–387
  6. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 2006;58:488–520
  7. Bender AT, Ostenson CL, Giordano D, Beavo JA. Differentiation of human monocytes in vitro with granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor produces distinct changes in cGMP phosphodiesterase expression. Cell. Signal. 2004;16:365–374
  8. Bielekova B, Lincoln A, McFarland H, Martin R. Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases. J. Immunol. 2000;164:1117–1124
  9. Bopp T, Becker C, Klein M, Klein-Hessling S, Palmetshofer A, Serfling E, et al. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J. Exp. Med. 2007;204:1303–1310
  10. Borger P, Kauffman HF, Postma DS, Vellenga E. Interleukin-4 gene expression in activated human T lymphocytes is regulated by the cyclic adenosine monophosphate-dependent signaling pathway. Blood. 1996;87:691–698
  11. Bright JJ, Du C, Coon M, Sriram S, Klaus SJ. Prevention of experimental allergic encephalomyelitis via inhibition of IL-12 signaling and IL-12-mediated Th1 differentiation: an effect of the novel anti-inflammatory drug lisofylline. J. Immunol. 1998;161:7015–7022
  12. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J. Clin. Invest. 2006;116:2843–2854
  13. Deibler GE, Martenson RE, Kies MW. Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species. Prep. Biochem. 1972;2:139–165
  14. Deval C, Mordier S, Obled C, Bechet D, Combaret L, Attaix D, et al. Identification of cathepsin L as a differentially expressed message associated with skeletal muscle wasting. Biochem. J. 2001;360:143–150
  15. D'Hellencourt CL, Diaw L, Cornillet P, Guenounou M. Differential regulation of TNF alpha, IL-1 beta, IL-6, IL-8, TNF beta, and IL-10 by pentoxifylline. Int. J. Immunopharmacol. 1996;18:739–748
  16. Dinter H, Tse J, Halks-Miller M, Asarnow D, Onuffer J, Faulds D, et al. The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents. J. Neuroimmunol. 2000;108:136–146
  17. Dominguez-Jimenez C, Sancho D, Nieto M, Montoya MC, Barreiro O, Sanchez-Madrid F, et al. Effect of pentoxifylline on polarization and migration of human leukocytes. J. Leukoc. Biol. 2002;71:588–596
  18. Dong RP, Umezawa Y, Ikushima H, Munakata Y, Schlossman SF, Morimoto C. Different regulatory effects of pentoxifylline on human T cell activation pathways. J. Clin. Immunol. 1997;17:247–252
  19. Ekholm D, Hemmer B, Gao G, Vergelli M, Martin R, Manganiello V. Differential expression of cyclic nucleotide phosphodiesterase 3 and 4 activities in human T cell clones specific for myelin basic protein. J. Immunol. 1997;159:1520–1529
  20. Feferman T, Aricha R, Mizrachi K, Geron E, Alon R, Souroujon MC, et al. Suppression of experimental autoimmune myasthenia gravis by inhibiting the signaling between IFN-gamma inducible protein 10 (IP-10) and its receptor CXCR3. J. Neuroimmunol. 2009;209:87–95
  21. Fleming CM, He H, Ciota A, Perkins D, Finn PW. Administration of pentoxifylline during allergen sensitization dissociates pulmonary allergic inflammation from airway hyperresponsiveness. J. Immunol. 2001;167:1703–1711
  22. Folcik VA, Smith T, O'Bryant S, Kawczak JA, Zhu B, Sakurai H, et al. Treatment with BBB022A or rolipram stabilizes the blood–brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors. J. Neuroimmunol. 1999;97:119–128
  23. Galboiz Y, Shapiro S, Lahat N, Rawashdeh H, Miller A. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann. Neurol. 2001;50:443–451
  24. Galindo-Rodriguez G, Bustamante R, Esquivel-Nava G, Salazar-Exaire D, Vela-Ojeda J, Vadillo-Buenfil M, et al. Pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis. J. Rheumatol. 2003;30:2382–2384
  25. Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, Beavo JA, et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature. 2007;445:771–775
  26. Haddad JJ, Land SC, Tarnow-Mordi WO, Zembala M, Kowalczyk D, Lauterbach R. Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-alpha) biosynthesis in alveolar epithelial cells. J. Pharmacol. Exp. Ther. 2002;300:559–566
  27. Hinkle RT, Dolan E, Cody DB, Bauer MB, Isfort RJ. Phosphodiesterase 4 inhibition reduces skeletal muscle atrophy. Muscle Nerve. 2005;32:775–781
  28. Hofstetter HH, Karulin AY, Forsthuber TG, Ott PA, Tary-Lehmann M, Lehmann PV. The cytokine signature of MOG-specific CD4 cells in the EAE of C57BL/6 mice. J. Neuroimmunol. 2005;170:105–114
  29. Hurwitz RL, Hirsch KM, Clark DJ, Holcombe VN, Hurwitz MY. Induction of a calcium/calmodulin-dependent phosphodiesterase during phytohemagglutinin-stimulated lymphocyte mitogenesis. J. Biol. Chem. 1990;265:8901–8907
  30. Kammer GM. The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol. Today. 1988;9:222–229
  31. Kanda N, Watanabe S. Regulatory roles of adenylate cyclase and cyclic nucleotide phosphodiesterases 1 and 4 in interleukin-13 production by activated human T cells. Biochem. Pharmacol. 2001;62:495–507
  32. Koh WS, Yang KH, Kaminski NE. Cyclic AMP is an essential factor in immune responses. Biochem. Biophys. Res. Commun. 1995;206:703–709
  33. Laurat E, Poirier B, Tupin E, Caligiuri G, Hansson GK, Bariety J, et al. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation. 2001;104:197–202
  34. Lennon VA, Lambert EH, Leiby KR, Okarma TB, Talib S. Recombinant human acetylcholine receptor alpha-subunit induces chronic experimental autoimmune myasthenia gravis. J. Immunol. 1991;146:2245–2248
  35. Lerner A, Epstein PM. Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies. Biochem. J. 2006;393:21–41
  36. Ma R, Yang BY, Wu CY. A selective phosphodiesterase 4 (PDE4) inhibitor Zl-n-91 suppresses IL-17 production by human memory Th17 cells. Int. Immunopharmacol. 2008;8:1408–1417
  37. MacDonald MJ, Shahidi NT, Allen DB, Lustig RH, Mitchell TL, Cornwell ST. Pentoxifylline in the treatment of children with new-onset type I diabetes mellitus. Jama. 1994;271:27–28
  38. Maksymowych WP, Avina-Zubieta A, Luong MH, Russell AS. An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis. J. Rheumatol. 1995;22:625–629
  39. Menon RT, Feferman T, Aricha R, Souroujon MC, Fuchs S. Suppression of experimental autoimmune myasthenia gravis by combination therapy: pentoxifylline as a steroid-sparing agent. J. Neuroimmunol. 2008;201–202:128–135
  40. Moore CS, Earl N, Frenette R, Styhler A, Mancini JA, Nicholson DW, et al. Peripheral phosphodiesterase 4 inhibition produced by 4-[2-(3,4-bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydrox ypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826, 141) prevents experimental autoimmune encephalomyelitis. J. Pharmacol. Exp. Ther. 2006;319:63–72
  41. Mor F, Cohen IR. Pathogenicity of T cells responsive to diverse cryptic epitopes of myelin basic protein in the Lewis rat. J. Immunol. 1995;155:3693–3699
  42. Navegantes LC, Resano NM, Migliorini RH, Kettelhut IC. Role of adrenoceptors and cAMP on the catecholamine-induced inhibition of proteolysis in rat skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 2000;279:E663–E668
  43. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983;13:227–231
  44. Reyes-Irisarri E, Sanchez AJ, Garcia-Merino JA, Mengod G. Selective induction of cAMP phosphodiesterase PDE4B2 expression in experimental autoimmune encephalomyelitis. J. Neuropathol. Exp. Neurol. 2007;66:923–931
  45. Rieckmann P, Weber F, Gunther A, Martin S, Bitsch A, Broocks A, et al. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J. Neuroimmunol. 1996;64:193–200
  46. Rott O, Cash E, Fleischer B. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur. J. Immunol. 1993;23:1745–1751
  47. Sadhu K, Hensley K, Florio VA, Wolda SL. Differential expression of the cyclic GMP-stimulated phosphodiesterase PDE2A in human venous and capillary endothelial cells. J. Histochem. Cytochem. 1999;47:895–906
  48. Seybold J, Thomas D, Witzenrath M, Boral S, Hocke AC, Burger A, et al. Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability. Blood. 2005;105:3569–3576
  49. Shichijo M, Shimizu Y, Hiramatsu K, Inagaki N, Tagaki K, Nagai H. Cyclic AMP-elevating agents inhibit mite-antigen-induced IL-4 and IL-13 release from basophil-enriched leukocyte preparation. Int. Arch. Allergy Immunol. 1997;114:348–353
  50. Silva JC, Rocha MF, Lima AA, Brito GA, de Menezes DB, Rao VS. Effects of pentoxifylline and nabumetone on the serum levels of IL-1beta and TNFalpha in rats with adjuvant arthritis. Inflamm. Res. 2000;49:14–19
  51. Skapenko A, Leipe J, Lipsky PE, Schulze-Koops H. The role of the T cell in autoimmune inflammation. Arthritis Res. Ther. 2005;7(Suppl 2):S4–S14
  52. Sommer N, Martin R, McFarland HF, Quigley L, Cannella B, Raine CS, et al. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. J. Neuroimmunol. 1997;79:54–61
  53. Tasken K, Ruppelt A. Negative regulation of T-cell receptor activation by the cAMP-PKA-Csk signalling pathway in T-cell lipid rafts. Front. Biosci. 2006;11:2929–2939
  54. Tasken K, Stokka AJ. The molecular machinery for cAMP-dependent immunomodulation in T-cells. Biochem. Soc. Trans. 2006;34:476–479
  55. Torgersen KM, Vang T, Abrahamsen H, Yaqub S, Tasken K. Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell. Signal. 2002;14:1–9
  56. Voltz R, Hohlfeld R, Fateh-Moghadam A, Witt TN, Wick M, Reimers C, et al. Myasthenia gravis: measurement of anti-AChR autoantibodies using cell line TE671. Neurology. 1991;41:1836–1838
  57. Wacholtz MC, Minakuchi R, Lipsky PE. Characterization of the 3′,5′-cyclic adenosine monophosphate-mediated regulation of IL2 production by T cells and Jurkat cells. Cell. Immunol. 1991;135:285–298
  58. Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?. Ann. Neurol. 2009;65:239–248

PII: S0165-5728(10)00005-6

doi: 10.1016/j.jneuroim.2009.12.012

Journal of Neuroimmunology
Volume 220, Issue 1 , Pages 43-51 , 30 March 2010

Article Tools

* Image Usage & Resolution